523 related articles for article (PubMed ID: 28619428)
21. Neuromyelitis optica: clinical features, immunopathogenesis and treatment.
Jarius S; Wildemann B; Paul F
Clin Exp Immunol; 2014 May; 176(2):149-64. PubMed ID: 24666204
[TBL] [Abstract][Full Text] [Related]
22. [Neuromyelitis optica spectrum disorder: a case report].
Mitsuyama T; Yoneyama T; Suzuki S; Kagawa M; Kawamata T
No Shinkei Geka; 2012 Apr; 40(4):337-42. PubMed ID: 22466233
[TBL] [Abstract][Full Text] [Related]
23. Neuromyelitis optica.
Wingerchuk DM
Int MS J; 2006 May; 13(2):42-50. PubMed ID: 16635421
[TBL] [Abstract][Full Text] [Related]
24. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Roemer SF; Parisi JE; Lennon VA; Benarroch EE; Lassmann H; Bruck W; Mandler RN; Weinshenker BG; Pittock SJ; Wingerchuk DM; Lucchinetti CF
Brain; 2007 May; 130(Pt 5):1194-205. PubMed ID: 17282996
[TBL] [Abstract][Full Text] [Related]
25. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
Paul F; Jarius S; Aktas O; Bluthner M; Bauer O; Appelhans H; Franciotta D; Bergamaschi R; Littleton E; Palace J; Seelig HP; Hohlfeld R; Vincent A; Zipp F
PLoS Med; 2007 Apr; 4(4):e133. PubMed ID: 17439296
[TBL] [Abstract][Full Text] [Related]
26. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.
Jacob A; McKeon A; Nakashima I; Sato DK; Elsone L; Fujihara K; de Seze J
J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):922-30. PubMed ID: 23142960
[TBL] [Abstract][Full Text] [Related]
27. Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre study.
Domingos J; Isidoro L; Figueiredo R; Brum M; Capela C; Barros P; Santos E; Macário Mdo C; Pinto Marques J; Pedrosa R; Vale J; Sá MJ
Clin Neurol Neurosurg; 2015 Jul; 134():79-84. PubMed ID: 25965287
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
Lechner C; Baumann M; Hennes EM; Schanda K; Marquard K; Karenfort M; Leiz S; Pohl D; Venkateswaran S; Pritsch M; Koch J; Schimmel M; Häusler M; Klein A; Blaschek A; Thiels C; Lücke T; Gruber-Sedlmayr U; Kornek B; Hahn A; Leypoldt F; Sandrieser T; Gallwitz H; Stoffels J; Korenke C; Reindl M; Rostásy K
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):897-905. PubMed ID: 26645082
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic challenge in a man with intractable hiccups and vomiting: a case of neuromyelitis optica spectrum disorder (NMOSD)].
Kaloudi D; Svenningsson A; von Heijne A
Lakartidningen; 2019 Aug; 116():. PubMed ID: 31429915
[TBL] [Abstract][Full Text] [Related]
30. Revised diagnostic criteria for neuromyelitis optica.
Wingerchuk DM; Lennon VA; Pittock SJ; Lucchinetti CF; Weinshenker BG
Neurology; 2006 May; 66(10):1485-9. PubMed ID: 16717206
[TBL] [Abstract][Full Text] [Related]
31. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
Kitley J; Leite MI; Küker W; Quaghebeur G; George J; Waters P; Woodhall M; Vincent A; Palace J
JAMA Neurol; 2013 Nov; 70(11):1375-81. PubMed ID: 23999580
[TBL] [Abstract][Full Text] [Related]
32. The spectrum of neuromyelitis optica.
Wingerchuk DM; Lennon VA; Lucchinetti CF; Pittock SJ; Weinshenker BG
Lancet Neurol; 2007 Sep; 6(9):805-15. PubMed ID: 17706564
[TBL] [Abstract][Full Text] [Related]
33. Immunopathogenesis of neuromyelitis optica.
Levy M; Wildemann B; Jarius S; Orellano B; Sasidharan S; Weber MS; Stuve O
Adv Immunol; 2014; 121():213-42. PubMed ID: 24388217
[TBL] [Abstract][Full Text] [Related]
34. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
[TBL] [Abstract][Full Text] [Related]
35. The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.
Cheng C; Jiang Y; Lu X; Gu F; Kang Z; Dai Y; Lu Z; Hu X
BMC Neurol; 2016 Oct; 16(1):203. PubMed ID: 27769253
[TBL] [Abstract][Full Text] [Related]
36. [Neuromyelitis optica: a separate disease entity associated with aquaporin-4-antibodies].
Jordan B; Eger K; Kornhuber ME; Zierz S
Fortschr Neurol Psychiatr; 2008 Jan; 76(1):21-7. PubMed ID: 18189220
[TBL] [Abstract][Full Text] [Related]
37. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis.
Petzold A; Pittock S; Lennon V; Maggiore C; Weinshenker BG; Plant GT
J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):109-11. PubMed ID: 20019228
[TBL] [Abstract][Full Text] [Related]
38. Anti-aquaporin-4 antibody-positive definite neuromyelitis optica in a patient with thymectomy for myasthenia gravis.
Ogaki K; Hirayama T; Chijiiwa K; Fukae J; Furuya T; Noda K; Fujishima K; Hattori N; Takahashi T; Okuma Y
Neurologist; 2012 Mar; 18(2):76-9. PubMed ID: 22367834
[TBL] [Abstract][Full Text] [Related]
39. Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-aquaporin 4 antibodies.
Chang KH; Lyu RK; Chen CM; Wu YR; Chang HS; Huang CC; Kuo HC; Chu CC; Hsu WC; Ro LS
Mult Scler; 2013 Mar; 19(3):299-307. PubMed ID: 22829325
[TBL] [Abstract][Full Text] [Related]
40. [NMO-IgG antibodies in neuromyelitis optica: a report of 2 cases].
Zuliani L; López de Munain A; Ruiz Martínez J; Olascoaga J; Graus F; Saiz A
Neurologia; 2006; 21(6):314-7. PubMed ID: 16799907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
